Among the 14 patients with PIK3CA tumour mutations at diagnosis, 3/14 (21.4%) achieved a pCR after neoadjuvant chemotherapy, and 2/14 (14.3%) were non-responders (Table 2). The gene discussed is PIK3CA; the disease is neoplasm.